Advanced Microbubbles

Advanced Microbubbles is addressing the critical challenge of inefficient drug delivery in oncology, where less than 1% of injected drugs typically reach their target. Their core innovation is the creation of stable, large, monodisperse microbubbles that, when combined with ultrasound, can non-invasively open biological barriers to enable precise delivery of various therapeutic agents. The platform has shown promising preclinical results in models of pancreatic cancer, neuroblastoma, and for blood-brain barrier opening, positioning the company to advance a versatile, drug-agnostic delivery technology.

Proprietary platform for manufacturing size-isolated monodisperse microbubbles (SIMBs) used in combination with ultrasound to non-invasively and transiently open biological barriers (e.g., blood-brain barrier, tumor endothelium) for targeted drug and gene delivery.

Total raised: $16M

Main competitors include other ultrasound-focused drug delivery companies like CarThera and HistoSonics, as well as academic research groups. Advanced Microbubbles differentiates itself through its proprietary, monodisperse microbubble formulation (SIMBs), which it claims offers superior stability and more controlled bio-effects compared to standard polydisperse bubbles used by others.